Background:
A protective vaccine would be the most powerful tool towards reducing HIV-1 infections worldwide and sustainably ending the AIDS epidemic as a public health threat. We assessed the safety and immunogenicity of ConM SOSIP.v7, a native-like envelope trimer vaccine based on an HIV-1 group M consensus sequence, in HIV-negative adults.
Methods:
24 individuals were enrolled in a phase 1 clinical trial to receive three dosages of adjuvanted ConM SOSIP.v7 (baseline, eight and 24 weeks) and followed-up for one year thereafter. Out of 23 per-protocol vaccine recipients, 10 received a one-fifth fractional third dose, aimed to increase B cell somatic hypermutation. Outcomes included ConM-specific total immunoglobulin G (IgG), IgG subclasses, pseudovirus neutralisation and single B cell sequencing. Levels of sex hormones were measured over time.
Results:
The majority of adverse events were mild to moderate, self-limiting and similar between dosage groups and sexes. No serious adverse events were reported. Similar to non-human primates, adjuvanted ConM SOSIP.v7 was consistently capable of inducing an autologous neutralising antibody response in humans, which remained detectable in half of the participants six months after the final vaccination. Antibody binding to several heterologous envelope proteins could be detected in the majority of participants, but no neutralisation breath. No differences in serological outcomes could be attributed to the fractional third dose. Female born participants had an earlier increase in neutralising antibodies than males and had a 6.3-fold higher neutralisation titer post third vaccination. Sex-based differences in IgG1 and IgG4 subtype responses were also observed. Subtle correlations, both positive and negative, were seen between ConM-neutralisation, IgG2 and IgG3 levels on one hand, and oestradiol and testosterone on the other hand, but the small sample size limits drawing strong conclusions. Single B cell sequencing should reveal whether the fractional dose and/or sex influence B cell affinity maturation.
Conclusions:
The adjuvanted ConM SOSIP.v7 native-like trimer vaccine is safe and elicits a robust strain-specific neutralising response in nearly all recipients, making it an interesting boosting immunogen candidate. Females responded earlier and had a striking 6.3-fold higher neutralisation titer after the final vaccination. This study highlights that sex-based differences should be taken into consideration when assessing HIV-1 vaccine candidates and adjuvants.
![]()